



Aarti Drugs Ltd.

AARTI DRUGS LIMITED

Investor Presentation September 2018



This investor presentation has been prepared by Aarti Drugs Limited (“ADL”) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be deemed to constitute an offer.


No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be “forward looking statements”, including those relating to the general business plans and strategy of ADL, its future financial condition and growth prospects, future developments in its industry and its competitive and regulatory environment, and statements which contain words or phrases such as ‘will’, ‘expected to’, ‘horizons of growth’, ‘strong growth prospects’, etc., or similar expressions or variations of such expressions. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to risks with respect to its hair care, its healthcare business and its skin care business.

ADL may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and disseminated in any manner.

Table of content




01	Company Overview	03 - 15
02	Pharmaceutical Industry Overview & Growth Drivers	16 - 19
03	Investment Proposition & Outlook	20 - 22
04	R & D Product Pipeline	23 - 25
05	Result Summary	26 - 29
06	Financial Overview	30 - 35
07	Shareholder Information	36 - 37



Company Overview


Aarti Drugs Limited was established in the year 1984 and forms part of \$790 Million Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates and Specialty Chemicals with its wholly-owned subsidiary- Pinnacle Life Science Private Limited. Products under APIs includes Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc.

We shall become the first choice vendor of Bulk Drugs and achieve a leadership position by:



Mission

- Seek global market leadership
- Focus on growth and development of the product
- Continue to create winning culture, operating in highest standards of ethics and values with co-operation among competitors
- Strive for excellence in customer service, quality and R&D



12
Manufacturing facilities



100
Countries



1,145
Employees



50+
API Molecules



80+
Finished Products






~37%
Export revenue




2,143 MT
Monthly Total Capacity



43,852 Sq.M
Plant Area



Number In ₹ Million



1991-92



CHEMEXCIL

Outstanding Performance in Export

2001



CHEMEXCIL

Outstanding Performance in Export

ORGANIZATION OF PHARMACEUTICAL PRODUCT
Best Vendor

2005



AVAYA GLOBAL CONNECT

Customer Responsiveness

2006



AVAYA GLOBAL CONNECT

Customer Responsiveness

2009



PHARMEXCIL

Outstanding Performance in Export

2012



PHARMEXCIL

Outstanding Performance in Latin American Export

2013



ABBOTT

Best Vendor of the year

2014



ABBOTT

Appreciation as business partner

2014



Government of India(Ministry of commerce and Industry)

Certificate of Recognition –Star Export House

2015



ABBOTT

Business partner of the year

2016



ABBOTT

Business partner of the year

2017



ABBOTT

Business partner of the year

Education Welfare



Medical Welfare



Dam Construction at Palghar





Mr. Prakash M. Patil
Chairman, MD & CEO

Shri Prakash M. Patil is Chairman, Managing Director and Chief Executive officer (CEO) of the Company and has been associated since inception of the Company's operations. He holds a degree of B.E. – Chemical from Institute of Chemical Technology (ICT) [formerly known as University Department of Chemical Technology]. He has more than 40 years of experience in the field of Chemical & Pharmaceutical Industry. He has expertise in Product Identification, Project Conceptualisation, Planning, Project Engineering & Implementation. His technical experience has helped the Company to emerge as one of the leading Pharmaceutical Company in the country.



Mr. Harshit M. Savla
Joint Managing Director

Shri Harshit M. Savla is Joint Managing Director of the Company. He is a Commerce Graduate having more than 30 years of experience in Finance, Export and Administration. He played crucial role in expanding the export market for the products of the Company.



Mr. Harit P. Shah
Whole Time Director

Shri Harit P. Shah is a Whole-time Director of the Company. He is a Commerce Graduate and has experience of over 25 years in handling commercial functions encompassing Purchases, Local Sales and Exports.



Mr. Rashesh C. Gogri
Managing Director

Shri Rashesh C. Gogri has been appointed as Managing Director of the Company with effect from 26th September, 2014. He was the Whole-time Director of the Company since October, 2012. He holds a Production Engineering degree from Mumbai University. He has more than 16 years of experience in field of production, marketing and project implementation in chemical industry. He also serves as Vice – Chairman & Managing Director of Aarti Industries Limited.




Mr. Adhish P. Patil
Chief Financial Officer

Shri Adhish P. Patil has experience of over 13 years in the field of finance, consulting, systems engineering and Information Technology. Bachelor of Engineering (IT) from Mumbai University. He is an MBA - Finance & Marketing from University of Florida, Warrington College of Business Administration. He is the winner of prestigious 'Top 100 CFOs India 2014' award.




Segment-wise Revenue Split

Period Ended Sept,18




FY 17-18




Therapeutic wise Sales of the API Segment

Period Ended Sept,18




FY 17-18





Monthly Capacity
2143 Mt/m

Particulars	2017-18	2016-17
Units	mt	mt
Installed	25,714	22,582
Production	19,261	17,463
Captive	3,925	4,053
Net Production	15,337	13,410



1. Aarti Drugs Ltd.E-22

- Australian Government – Department of Health and Ageing - Therapeutic Goods Administration
- EUGMP / WHO-GMP / Japanese Accreditation
- USFDA * Import alert dated 23rd Mar'15

2. Aarti Drugs Ltd.G-60

- ANVISA-Brazil
- WHO-GMP
- COFEPRIS-MEXICO

3. Aarti Drugs Ltd.E-21

- WHO-GMP
- K-FDA(Korean FDA)

4. Aarti Drugs Ltd.N-198

- EUGMP, WHO-GMP & ISO Certification

5. Aarti Drugs Ltd.K-40

- WHO-GMP / COFEPRIS

6. Aarti Drugs Ltd.W-61(Suyash)

- EUGMP & WHO-GMP

7. Aarti Drugs Ltd.E-120


- WHO-GMP

8. Aarti Drugs Ltd.E-9/3(Rashesh)

- ISO-9001:2008

9. Aarti Drugs Ltd T-150

- Intermediate Plant



1. Aarti Drugs Ltd-Sarigam 2902-04

- WHO-GMP

2. Aarti Drugs Ltd-Sarigam 211/213


- WHO-GMP / COFEPRIS / CEP

Global

- | | | |
|-------------------|-----------------------|----------------------|
| 1 Albania | 40 Italy | 80 Sri Lanka |
| 2 Algeria | 41 Ivory Coast | 81 Sudan |
| 3 Argentina | 42 Jamaica | 82 Sultanate of Oman |
| 4 Australia | 43 Japan | 83 Switzerland |
| 5 Bangladesh | 44 Jordan | 84 Syria |
| 6 Belarus | 45 Kenya | 85 Taiwan |
| 7 Belgium | 46 Korea | 86 Tanzania |
| 8 Benin | 47 Kuwait | 87 Thailand |
| 9 Bolivia | 48 Latvia | 88 Tunisia |
| 10 Bosnia | 49 Lebanon | 89 Turkey |
| 11 Brazil | 50 Lithuania | 90 U.A.E. |
| 12 Bulgaria | 51 Macedonia | 91 U.K. |
| 13 Burundi | 52 Malaysia | 92 U.S.A. |
| 14 Canada | 53 Mexico | 93 Uganda |
| 15 Chile | 54 Moldova | 94 Ukraine |
| 16 China | 55 Morocco | 95 Uruguay |
| 17 Colombia | 56 Nepal | 96 Uzbekistan |
| 18 Costa Rica | 57 Netherlands | 97 Venezuela |
| 19 Croatia | 58 New Zealand | 98 Vietnam |
| 20 Cuba | 59 Nicaragua | 99 Yugoslavia |
| 21 Cyprus | 60 Nigeria | 100 Zimbabwe |
| 22 Czech Republic | 61 Pakistan | |
| 23 Ecuador | 62 Panama | |
| 24 Egypt | 63 Paraguay | |
| 25 El Salvador | 64 Peru | |
| 26 Ethiopia | 65 Philippines | |
| 27 France | 66 Poland | |
| 28 Georgia | 67 Portugal | |
| 29 Germany | 68 Puerto Rico | |
| 30 Greece | 69 Rep. of Dominic | |
| 31 Guatemala | 70 Rep. of Kazakhstan | |
| 32 Hongkong | 71 Rep. of Yemen | |
| 33 Hungary | 72 Romania | |
| 34 India | 73 Russia | |
| 35 Indonesia | 74 S. Africa | |
| 36 Iran | 75 Saudi Arabia | |
| 37 Iraq | 76 Singapore | |
| 38 Ireland | 77 Slovakia | |
| 39 Israel | 78 Slovenia | |
| | 79 Spain | |

India

- | | |
|--------------------|------------------------------|
| 1 Maharashtra | 12 Jammu & Kashmir |
| 2 Gujarat | 13 West Bengal |
| 3 Uttar Pradesh | 14 Goa (* Union Territory) |
| 4 Himachal Pradesh | 15 Daman (* Union Territory) |
| 5 Uttarakhand | 16 Kerala |
| 6 Tamil Nadu | 17 Odisha |
| 7 Andhra Pradesh | 18 Assam |
| 8 Sikkim | 19 Punjab |
| 9 Karnataka | 20 Rajasthan |
| 10 Delhi | 21 Haryana |
| 11 Madhya Pradesh | 22 Chandigarh |



TOP 10 EXPORT COUNTRIES

Country	BRAZIL	MEXICO	PAKISTAN	TURKEY	INDONESIA
	BANGLADESH	VIETNAM	CHINA	SPAIN	EGYPT

Market

Regulated	56%
Semi-Regulated	26%
Non - Regulated	18%

Notes: All numbers in % denotes revenue share of total Exports





Pharmaceutical Industry Overview & Growth Drivers

Active Pharmaceutical Ingredients (APIs)



- India has become the third largest global generic API merchant market by 2016, with a 7.2 per cent market share
- The Indian pharmaceutical industry accounts for the 2nd largest number of Abbreviated New Drug Applications (ANDAs), is the world's leader in Drug Master Files (DMFs) applications with the US



Contract Research and Manufacturing Services (CRAMS)



- Fragmented market with more than 1,000 players
- CRAMS industry is estimated to reach US\$ 18 billion in 2018 and expected to witness a strong growth at a CAGR of 18-20 per cent between 2013-2018

Formulations



- Largest exporter of formulations in terms of volume, with 14 per cent market share and 12th in terms of export value
- Domestic market size currently valued at US\$ 11.2 billion
- Double-digit growth expected over the next 5 years





Biosimilars




- The government plans to allocate US\$ 70 million for local players to develop Biosimilars
- The domestic market is expected to reach US\$ 40 billion by 2030

API is the largest segment of the Indian pharmaceuticals sector

Pharmaceutical Exports



Indian Pharmaceutical Market Growth



Source :IBEF, Pharmaceuticals Export Promotion Council of India



Indian pharmaceutical



3.1 – 3.6 per cent of the global pharmaceutical industry in value



10 per cent in volume

By 2020

Top 3 pharmaceutical markets by incremental growth

6th largest market globally in absolute size.

US\$100 billion by 2025

- Over US\$ 200 billion to be spent on medical infrastructure in the next decade
- New business models expected to penetrate tier-2 and 3 cities
- Over 160,000 hospital beds expected to be added each year in the next decade
- India's generic drugs account for 20 per cent of global exports in terms of volume, making the country the largest provider of generic medicines globally

- Rising income could drive 73 million households to the middle class over the next 10 years
- Over 650 million people expected to be covered by health insurance by 2020
- Government-sponsored programmes set to provide health benefits to over 380 million BPL people by the end of 2017
- The government plans to provide free generic medicines to half the population at an estimated cost of US\$ 5.4 billion



- Rising levels of education to increase acceptability of pharmaceuticals
- Patients to show greater propensity to self-medicate, boosting the OTC market
- Acceptance of biologics and preventive medicines to rise
- A skilled workforce as well as high managerial and technical competence
- Surge in medical tourism due to increased patient inflow from other countries

- Patient pool expected to increase over 20 per cent in the next 10 years, mainly due to rise in population
- New diseases and lifestyle changes to boost demand
- Increasing prevalence of lifestyle diseases



Investment Proposition & Outlook

Known brand in API space

Reliable in terms of quality and timely deliveries. Honouring commitments in changing market conditions.

Strong process improvement R&D, cost leadership, huge client base

Thus, fundamentals right from procurement, production till sales have a strong foundation and sound setup.

Phase-wise CAPEX to mitigating debt trap risks

Newer capacities established since last two years will help grow top-line.

Green field projects


Company has good amount of land parcels in industrial zones in Maharashtra and Gujarat which can take care of green field projects in next 3 to 4 years.

Entry barrier

Around 100 cr CAPEX is being done every year to fuel growth for coming 5 years considering higher gestation period in API business due to continuous tightening of regulatory norms. This in turn creates entry barrier for newer players.

Key Competitive Factors

Top 10 products contributes to **~75%** of Revenues



Anti diabetic

- Started with the commercial operations, received WHOGMP, recently inspected by COFEPRIS
- CEP approval in 2016 which opened up European markets
- Expected revenues of installed phase I capacity would be ~150 cr per annum as per ROW market pricing. Started with 2nd phase expansion (FY18-19) of doubling of capacity since phase 1 capacity is completely utilized. After 2nd phase completion will be largest metformin player.

Leading manufacturer of Fluoro-quinolones (# 5 products)

- Only backward integrated player in Indian market
- GOI recently introduced antidumping duty on ofloxacin

Antiprotozoal

- Doubled the capacity of existing product to curtail the imports. Existing technology and Chinese JV.
- Established competitive edge worldwide and sole Indian player.
- Incremental expansions and downstream products expansion is going on.

Vitamins / Anti-inflammatory

- Multi-purpose facility under construction. Targeting highly regulated markets.
- Installed capacity will give revenues of around 50 cr/ 35 cr per annum as per product selection - currently on HOLD.

Anti-fungal

Further expansion of one of our anti-fungal product where we are global market leaders to establish further dominance in this product. Backward integrated product wherein we also manufacture intermediate of this product.

Speciality chemicals

Further expansion of our chloro-sulphonation line for multiple products planned in FY18-19.

R&D product pipeline

- Strong pipeline of products under R&D for future growth
- Contract manufacturing of specialty chemicals and intermediates

Formulations

- Value addition to existing API products
- Toll manufacturing of formulations
- Started with commercial operations in Latin America, selective African markets. Doing new registrations in export markets and government tenders
- 30+ SKU's

Tie-ups

- Tied up with European distributor on profit sharing basis. Market authorisation of UK market for finished products of 2 molecules obtained and expect to do a launch FY18-19. 1 more in pipeline.
- Partnered with USA company on formulation revenues wherein we would be supplying api at cost.

Recent launch of phase I of multipurpose facility in Tarapur

Commercial operations of phase I started in feb'18 and slowly capacity will be ramped up. Second phase CAPEX would be planned soon most probably in FY19-20 financial year. This is designed for European markets. This facility can manufacture a range of products from anti-inflammatory, anti-fungal, anti-diarrheal, cardiovascular etc



R & D and Product Pipeline



Manufacturing facilities at Tarapur and Sarigam are supported by R&D section located at Tarapur, where focus is mainly on process developments

Strength at R&D

02

Doctorates

70

Master Graduates
[M. Sc]

09

Graduates
[B. Sc]

18

Engineer

10

Technicians

Pilot plant facility at Tarapur, which is suitable to produce products on kilo scale.


ADL R&D is well supported by in house project management team to ensure timely implementation of new products on commercial scale.

In last three year about 30 API's (New and Existing) have been developed in lab.

R&D Center recognized by Department by Science and Industrial Research (DSIR), Government of India.

Frequent visits of Experts and Professors from ICT and Council of Scientific and Industrial Research (CSIR) for guidance for product development.

R&D Expenses as % of Revenue



Year	Revenue
2014	9,718
2015	10,969
2016	11,398
2017	11,992
2018	12,447

Number In ₹ Million

Product Under Development

Sr. No.	Therapeutic Category	Products
1	Alcoholism Treatment	Acamprosate
2	Anticoagulant	Dabigatran
1	Anti Cholesterol	Atorvastatin
5	Dietary Supplement	Homotaurine
6	Anti Fungal	Itraconazole
7	Anti Fungal	Luliconazole
8	Anti Hypertensive	Telmisartan
9	Pharma RM	1, 2, 4-Triazole

Product Under Pipeline




Sr. No.	Therapeutic Category	Products
1	Cardiovascular	Olmesartan
2	Antidiabetic	Teneligliptin
3	Antidiabetic	Sitagliptin



Result Summary

(in ₹ Million)

Particulars	Q2 FY 19	Q1 FY 19	Q2 FY18	Y-o-Y (%)	FY 18	FY 17	Y-o-Y (%)
Revenue from Operations	3,474.10	3,742.89	3,192.69	9%	12,436.30	11,951.70	4%
Other Income	0.98	9.20	0.83	17%	10.50	40.00	-74%
Total Income	3,475.07	3,752.09	3,193.53	9%	12,446.80	11,991.70	4%
Expenses	3,004.14	3,216.80	2,667.33	13%	10,451.60	10,082.80	4%
Profit from Operations before Other Income, Finance Costs, Exceptional Items and Depreciation	470.94	535.28	526.19	-11%	1,995.20	1,908.90	5%
Depreciation and Amortisation Expenses	106.28	104.04	100.57	6%	400.60	384.60	4%
Finance Costs	97.34	94.07	80.31	21%	349.60	364.20	-4%
Profit from Ordinary Activities before Exceptional Item and Tax	267.32	337.17	345.31	-23%	1,245.00	1,160.10	7%
Exceptional Item	-	-	-	-	-	-	-
Profit Before Tax	267.32	337.17	345.31	-23%	1,245.00	1,160.10	7%
Tax	86.82	103.43	109.30	-21%	422.00	342.10	23%
Net Profit for the Period	180.50	233.74	236.01	-24%	823.00	818.00	1%
Other Comprehensive Income	-	-	-	-	-2.70	-10.90	-75%
Total Comprehensive Income for the Period	180.50	233.74	236.01	-24%	820.30	807.10	2%
Paid Up Equity Share Capital (Face Value of Rs 10 each)	235.8	235.8	238.6		235.80	238.60	
Earning Per Share Basic	7.65	9.82	9.89		34.41	33.46	
Earning Per Share Diluted	7.65	9.82	9.89		34.41	33.46	



API



Formulation



Specialty Chemicals






Intermediate & Others



Q2'19	2,840	370	86	178
Q2'18	2,568	424	68	132

Note: 1.. On Consolidated Basis 2. Revenue excluding excise duty 3. EBITDA is including other income
Number In ₹ Million

4. Regrouping has been done wherever necessary



API



Formulation



Specialty Chemicals



Intermediate & Others




FY18	10,168	1,390	303	576
FY17	9,609	1,550	434	359

Note: On Consolidated Basis Number In ₹ Million EBITDA is including other income PAT is before minority




Financial Overview


Revenue




EBITDA & EBITDA Margin



PBT & PBT Margin




PAT & PAT Margin




All numbers are on Consolidated basis

Number In ₹ Million


Earning Per Share




Gearing Ratio (x)



Net Worth



RoE(%) & RoCE (%)



All numbers are on Consolidated basis

ROE = Profit after tax / Average shareholder equity; RoCE = (Net Profit before Tax, Exceptional and extraordinary items + Finance cost) / Average (Net debt + Networkth)

Net Debt = Long term debt + short term debt + current maturities of long term debt

1:1 Bonus was issued in 2014-15

Number In ₹ Million, except per share data

(in ₹ Million)

Particulars	2018	2017	2016	2015	2014
Revenue from operations (gross)	12,625.70	12,880.80	12,283.05	11,796.03	10,443.46
Less : Excise duty	-189.40	-929.10	-934.23	-853.31	-744.09
Revenue from operations (net)	12,436.30	11,951.70	11,348.82	10,942.72	9,699.37
Other Income	10.50	40.00	49.58	32.62	18.28
Total Revenue	12,446.80	11,991.70	11,398.40	10,975.34	9,717.65
Expenses					
Cost of material consumed	7,977.70	7,402.00	7,210.21	6,901.92	5,708.20
Purchases of traded goods	397.60	406.80	505.99	869.88	860.25
(Increase)/decrease in Inventories of finished goods work in progress & stock in trade	-548.70	-4.30	-49.14	-272.99	56.86
Employee benefits expense	579.40	528.30	447.55	379.28	324.06
Finance cost	349.60	364.20	438.87	389.30	334.90
Depreciation & amortization expense	400.60	384.60	365.28	310.22	281.19
Other Expenses	2,045.60	1,750.00	1,526.89	1,400.53	1,304.58
Total Expenses	11,201.80	10,831.60	10,445.65	9,978.14	8,870.04
Profit/(loss) before tax	1,245.00	1,160.10	952.75	997.19	847.61
Tax Expense:					
Current tax (MAT)	328.00	291.30	211.50	210.00	230.00
MAT credit entitlement	-	-	-	-10.00	-
Taxation for earlier years	-	-20.30	-	-15.35	-25.35
Deferred tax	94.00	71.10	54.00	40.00	35.00
Total tax expense	422.00	342.10	265.50	224.65	239.65
Net profit/(loss) after tax	823.00	818.00	687.25	772.54	607.96
Extraordinary Items					
Other Comprehensive Income/(Loss)	-2.70	-10.90	-	-	-
Total Comprehensive Income for the Period	820.30	807.10	687.25	772.54	617.13
Paid up Equity Share Capital (Face Value of Rs 10 each)	235.80	238.60	242.17	242.17	121.10
Earnings Per Share (EPS) in Rupees					
-Basic	34.41	33.46	28.38	31.90	50.97
-Diluted	34.41	33.46	28.38	31.90	50.97

Note: Revenue excluding excise duty

(in ₹ Million)

Particulars	2018	2017	2016	2015	2014
Share Capital	235.80	238.60	242.17	242.17	121.09
Other Equity-Reserves & Surplus	4,318.50	3,762.80	3,224.45	2,839.36	2,387.95
Total Shareholders Fund	4,554.30	4,001.40	3,466.62	3,081.53	2,509.04
Non - Current Liabilities					
Long term borrowings	2,027.00	2,015.50	1,912.34	1,634.75	766.42
Deferred tax liability (Net)	809.20	717.70	646.21	350.18	310.12
Other Long term liabilities	118.10	148.80	107.08	122.47	115.09
Long term provisions	168.70	83.90	25.14	2.90	-
Total Non Current Liabilities	3,123.00	2,965.90	2,690.77	2,110.29	1,191.63
Current Liabilities					
Short term borrowings	3,056.40	2,446.60	2,584.09	2,524.27	2,655.98
Trade Payables-total outstanding dues of creditors other than micro enterprises and small enterprises	2,587.30	1,969.70	1,848.99	1,667.25	1,501.78
Other current liabilities	549.40	510.00	563.72	415.27	441.85
Short term provisions	8.90	16.80	2.45	220.80	197.14
Total Current Liabilities	6,202.00	4,943.10	4,999.24	4,827.60	4,796.75
Total	13,879.30	11,910.40	11,156.64	10,019.42	8,497.41
ASSETS					
Non - Current Assets					
Fixed Assets					
Tangible assets	5,978.40	5,750.10	4,863.79	4,484.64	3,725.26
Intangible assets	45.50	60.80	70.37	-	-
Capital work in progress	284.50	142.80	340.45	160.58	83.16
Non-current Investments	107.60	119.40	128.32	46.32	46.19
Long term loans and advances	-	-	-	72.44	70.43
Other non-current assets	109.50	123.00	101.47	-	-
Total Non Current Assets	6,525.50	6,196.10	5,504.39	4,763.98	3,925.04
Current Assets					
Inventories	2,782.10	2,096.30	1,783.50	1,641.96	1,267.26
Trade receivables	3,734.60	2,968.10	3,316.87	3,142.73	2,765.21
Cash & bank balances	42.70	41.70	48.21	35.80	43.98
Short term loans & advances	128.30	197.90	192.39	176.46	222.06
Other current assets	666.10	410.20	311.28	258.48	273.87
Total Current Assets	7,353.80	5,714.20	5,652.25	5,255.44	4,572.38
Total	13,879.30	11,910.30	11,156.64	10,019.42	8,497.41

Cash Flow Statement



Aarti Drugs Ltd.

(in ₹ Million)

	Particulars	2018	2017	2016	2015	2014
A	Cash Flow from Operating Activities					
	Net Profit before Tax and Extraordinary items	1,245.03	1,160.12	952.75	997.20	847.60
	ADJUSTMENT FOR:	-	-	-	-	-
	Depreciation & Amortisation	400.63	384.63	365.28	310.22	281.19
	Provision for Bad & doubtful Debts/ Bad debts	13.27	15.72	-	-	-
	Unrealised Foreign Exchange (Gain)/Losses (Net)	-8.97	-25.93	-	-	-
	Re- measurement losses on employee defined benefit plans	6.67	-12.39	-	-	-
	Depreciation on Revalued Assets	-	-2.60	-2.60	-1.38	-
	Interest Paid	349.61	364.21	438.87	389.30	334.90
	Interest Received	-9.93	-5.37	-8.52	-4.19	-13.22
	Dividend Received	-0.04	-0.03	-	-	-0.19
	Investment W/Off	-	19.31	-	-	-
	Gain on Sale of Investment	-	-4.48	-	-	-
	Loss on Sale of Investment	-	-	-	-	0.50
	Loss on Sale of Asset	-	-16.78	0.02	-	0.81
	Extraordinary items	-	-	-	-	9.17
	Operating Profit before Working Capital Changes	1,996.27	1,876.41	1,745.79	1,691.15	1,460.74
	Trade and other Receivable	-810.50	373.86	-190.11	-302.89	-617.02
	Change in Inventories	-683.81	-312.66	-140.12	-364.45	141.93
	Trade and other Payable	439.60	23.54	117.73	171.51	234.17
	Cash Generated from operation	941.56	1,961.14	1,533.29	1,195.32	1,219.83
	Direct Taxes Paid	-246.70	-213.60	-200.23	-149.41	-265.57
	Net Cashflow from Operating Activities	694.85	1,747.54	1,333.06	1,045.91	954.26
B	Cash Flow from Investing Activities					
	Purchase of Fixed Assets/Capital Work in Progress/Advances	-745.33	-1,087.93	-996.58	-1,069.81	-1,065.23
	Sale/(Purchase) of Investment	-	-4.01	-0.03	-125.52	4.63
	Sale of Fixed Assets	-	16.78	0.02	-	0.50
	Right Share Issue	-	-	-	121.07	-
	Interest Received	9.93	5.37	8.52	4.19	13.22
	Dividend Received	0.04	0.03	0.12	-	0.19
	Net Cash Flow from Investing Activities	-735.36	-1,069.76	-987.95	-1,070.08	-1,046.67
C	Cash Flow From Financing Activities					
	Proceeds from Long Term Borrowings	48.80	89.37	280.17	793.12	75.61
	Proceeds from Unsecured Loans from Scheduled Bank	609.78	-137.44	62.22	-162.51	506.14
	Buyback of Shares	-240.63	-270.00	-	-	-
	Dividend Paid	-24.32	-	-236.12	-226.68	-139.25
	Dividend Tax Paid	-4.86	-	-	-	-
	Interest Paid	-349.61	-364.21	-438.87	-389.30	-334.90
	Net Cash Flow from Financing Activities	39.15	-682.30	-332.59	14.63	107.61
	Net Increase in Cash & Cash Equivalents (A+B+C)	-1.35	-4.51	12.52	-9.53	15.18
	Opening Cash and Cash Equivalents	34.27	35.96	35.80	45.33	28.79
	Closing Cash and Cash Equivalents	32.92	31.45	48.21	35.80	43.97




Shareholder Information

Stock Data (As on 1st November 2018)

 Market Capitalization (₹)	14,272 mn
 Shares Outstanding	23.58 mn
 Free Float	37.57%
 Symbol (NSE/ BSE)	AARTIDRUGS / 524348


Stock Performance Chart (As on 05th June 2018)



Source: Factset, Thomson Reuters

Top Institutional Holders (As on 30th September 2018)

Institutions	OS (%)
DSP BlackRock Investment Managers Pvt Ltd.	3.68
Lakshmi Capital Investment Limited	0.43



Note: Data mentioned in above chart is as on 30th September 2018



Thank You

Aarti Drugs Ltd

Mahendra Inds. Estate, Ground Floor, Plot No. 109-D Road No. 29, Sion (E),
Mumbai-400 022 (India)

Tel: +91 22 24019025 / 24072249

Fax: +91 22 24073462 / 24070144

E-mail: investorrelations@aartidrugs.com